- Home
- MOH vs EXEL Comparison
MOH vs EXEL Comparison
Compare MOH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOH
- EXEL
- Stock Information
- Founded
- MOH 1980
- EXEL 1994
- Country
- MOH United States
- EXEL United States
- Employees
- MOH N/A
- EXEL N/A
- Industry
- MOH Medical Specialities
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOH Health Care
- EXEL Health Care
- Exchange
- MOH Nasdaq
- EXEL Nasdaq
- Market Cap
- MOH 10.5B
- EXEL 10.4B
- IPO Year
- MOH 2003
- EXEL 2000
- Fundamental
- Price
- MOH $156.00
- EXEL $39.50
- Analyst Decision
- MOH Hold
- EXEL Buy
- Analyst Count
- MOH 13
- EXEL 22
- Target Price
- MOH $211.17
- EXEL $44.10
- AVG Volume (30 Days)
- MOH 1.7M
- EXEL 2.9M
- Earning Date
- MOH 10-22-2025
- EXEL 11-04-2025
- Dividend Yield
- MOH N/A
- EXEL N/A
- EPS Growth
- MOH N/A
- EXEL 81.76
- EPS
- MOH 16.24
- EXEL 2.08
- Revenue
- MOH $42,842,000,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- MOH $14.48
- EXEL $9.14
- Revenue Next Year
- MOH $6.17
- EXEL $12.59
- P/E Ratio
- MOH $9.87
- EXEL $18.99
- Revenue Growth
- MOH 14.11
- EXEL 10.73
- 52 Week Low
- MOH $151.95
- EXEL $28.30
- 52 Week High
- MOH $359.97
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- MOH 28.98
- EXEL 53.00
- Support Level
- MOH $152.25
- EXEL $33.76
- Resistance Level
- MOH $166.31
- EXEL $40.63
- Average True Range (ATR)
- MOH 5.91
- EXEL 1.26
- MACD
- MOH -4.60
- EXEL 0.21
- Stochastic Oscillator
- MOH 7.98
- EXEL 83.62
About MOH Molina Healthcare Inc
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.